• 1
    Rao AR, Motiwala HG, Karim OM. The discovery of prostate specific antigen. BJU Int 2008; 101: 510
  • 2
    Stamey TA, Yang N, Hay AR et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 90916
  • 3
    Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 115661
  • 4
    Brawer MK, Chetner MP, Beatie J et al. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992; 147: 8415
  • 5
    Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA 2003; 289: 141420
  • 6
    Boyle P. Screening for prostate cancer: have you had your cholesterol measured? BJU Int 2003; 92: 1919
  • 7
    Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery – What we have learned and where we are going. J Urol 1999; 162: 293303
  • 8
    Söletormos G, Semjonow A, Sibley PE et al. Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin Chem 2005; 51: 134251
  • 9
    Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≥4.0 ng per millilitre. N Engl J Med 2004; 350: 223946
  • 10
    Damber J-E, Aus G. Prostate cancer. Lancet 2008; 371: 171021
  • 11
    De Angelis G, Rittenhouse HG, Mikolajczyk BA et al. Twenty years of PSA: from prostate antigen to tumor marker. Rev Urol 2007; 9: 11323
  • 12
    Cooner WH, Mosley BR, Rutherford CL Jr et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 1990; 143: 114652
  • 13
    Labrie F, Dupont A, Suburu R et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 1992; 147: 84651
  • 14
    Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6–4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997; 277: 14525
  • 15
    Carter HB, Pearson JD, Metter EJ et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 221520
  • 16
    Smith DS, Catalona WJ. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 1994; 152: 11637
  • 17
    Yu X, Han M, Loeb S et al. Comparison of methods for calculating prostate specific antigen velocity. J Urol 2006; 176: 242731
  • 18
    King CR, Freedland SJ, Terris MK et al. Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH. Urology 2007; 69: 7327
  • 19
    Connolly D, Black A, Murray L J et al. Methods of calculating prostate-specific antigen velocity. Eur Urol 2007; 52: 104451
  • 20
    Moul JW, Sun L, Hotaling JM et al. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol 2007; 177: 499503
  • 21
    Thompson IM, Ankerst DP, Chi C et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006; 98: 52934
  • 22
    Wolters T, Roobol MJ, Bangma CH, Schröder FH. Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam). Eur Urol 2008 March 11. [Epub ahead of print]
  • 23
    Ulmert D, Serio AM, O’Brien MF et al. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol 2008; 26: 83541
  • 24
    Connolly D, Black A, Murray LJ et al. The utility of prostate-specific antigen velocity thresholds in clinical practice: a population-based analysis. BJU Int 2008; 101: 150712
  • 25
    Eggener SE, Yossepowitch O, Roehl KA et al. Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program. Urology 2008; 71: 10169
  • 26
    D’Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 96974
  • 27
    Bianco FJ, Scardino PT, Eastham JA. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (‘Trifecta’). Urology 2005; 66 (Suppl. 5A): 8394
  • 28
    D’Amico AV, Moul J, Carroll PR et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003; 21: 216372
  • 29
    Kattan MW, Eastham JA, Stapleton AM et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90: 76671
  • 30
    Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999; 17: 1499507
  • 31
    D’Amico AV, Chen MH, Roehl KA et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351: 12535
  • 32
    Sengupta S, Myers RP, Slezak JM et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005; 174: 21916
  • 33
    D’Amico AV, Renshaw AA, Sussman B et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005; 294: 4407
  • 34
    Bianco FJ Jr, Kattan MW, Scardino PT. PSA velocity and prostate cancer. N Engl J Med 2004; 351: 18002
  • 35
    Loeb S, Sutherland DE, D’Amico AV. PSA velocity is associated with Gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness. Urology 2008; 72: 111620
  • 36
    Freedland SJ, Dorey F, Aronson WJ. Preoperative PSA velocity and doubling time do not predict adverse pathologic features or biochemical recurrence after radical prostatectomy. Urology 2001; 57: 47680
  • 37
    D’Amico AV, Hanks GE. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 1993; 72: 263843
  • 38
    Stephan C, Kramer J, Meyer H-A et al. Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies. BJU Int 2007; 99: 142731
  • 39
    Sengupta S, Slezak JM, Blute ML et al. Simple graphic method for estimation of prostate-specific antigen doubling time. Urology 2006; 67: 4089
  • 40
    Svatek RS, Shulman M, Choudhary PK, Benaim E. Critical analysis of prostate-specific antigen doubling time calculation methodology. Cancer 2006; 106: 104753
  • 41
    Daskivich TJ, Regan MM, Oh WK. Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4. J Urol 2006; 176: 192737
  • 42
    Arlen PM, Bianco F, Dahut WL et al. Prostate specific antigen working group guidelines on prostate specific antigen doubling time. J Urol 2008; 179: 21816
  • 43
    Pound CR, Partin AW, Eisenberger MA et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 15917
  • 44
    Roberts SG, Blute ML, Bergstralh E J et al. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001; 76: 57681
  • 45
    D’Amico AV, Moul J, Carroll PR et al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 2004; 172:S427
  • 46
    Freedland SJ, Humphreys EB, Mangold LA et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 4339
  • 47
    Zelefsky MJ, Ben-Porat L, Scher HI et al. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol 2005; 23: 82631
  • 48
    Zhou P, Chen M-H, McLeod D et al. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 2005; 23: 69928
  • 49
    D’Amico AV, Chen MH, Roehl KA et al. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol 2005; 23: 49759
  • 50
    Heidenreich A, Aus G, Bolla M et al. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 6880
  • 51
    Hussain M, Tangen CM, Higano C et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006; 24: 398490
  • 52
    Stamey TA, Kabalin JN, Ferrari M, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients. J Urol 1989; 141: 108890
  • 53
    Oosterlinck W, Mattelaer J, Casselman J et al. PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients. Acta Urol Belg 1997; 65: 6371
  • 54
    Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 151320
  • 55
    Berthold D, Pond GR, Soban F et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 2425
  • 56
    Kuriyama M, Wang M, Lee C et al. Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res 1981; 41: 38746
  • 57
    Kelly WK, Scher HI, Mazumdar M et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 60715
  • 58
    Smith DC, Dunn RL, Strawderman MS, Pienta KJ. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy of hormone-refractory prostate cancer. J Clin Oncol 1998; 16: 183543
  • 59
    Dowling AJ, Czaykowski PM, Krahn MD et al. Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice. J Urol 2000; 163: 14815
  • 60
    Small EJ, McMillan A, Meyer M et al. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end-points and survival. J Clin Oncol 2001; 19: 130411
  • 61
    Petrylak DP, Ankerst DP, Jiang CS et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006; 98: 51621
  • 62
    Armstrong AJ, Garrett-Mayer E, Ou Yang YC et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007; 25: 396570
  • 63
    Fossa SD, Vaage S, Letocha H et al. Liposomal doxorubicin (Caelyx) in symptomatic androgen-independent prostate cancer (AIPC): delayed response and flare phenomenon should be considered. Scand J Clin Oncol 2002; 36: 349
  • 64
    Olbert PJ, Hegele A, Kraeuter P et al. Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel. Anticancer Drugs 2006; 17: 9936
  • 65
    Thuret R, Massard C, Gross-Goupil M et al. The postchemotherapy PSA surge syndrome. Ann Oncol 2008; 19: 130811
  • 66
    Nelius T, Klatte T, De Riese W et al. Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy. Int Urol Nephrol 2008; 40: 97104
  • 67
    Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 114859
  • 68
    Hussain MH, Goldman B, Tangen CM et al. Use of prostate-specific antigen progression (PSA-P) to predict OS (OS) in patients (pts) with metastatic prostate cancer (PC): data from S9346 and S9916. J Clin Oncol 2008; 26 (Suppl.): 4565. Abstract 5015
  • 69
    Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 34617
  • 70
    Semeniuk RC, Venner PM, North S. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. Urology 2006; 68: 5659
  • 71
    Oudard S, Banu E, Scotte F et al. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann Oncol 2007; 18: 182833
  • 72
    Oudard S, Medioni J, Scotte F et al. What is the real impact of bone pain on survival in patients with hormone-refractory prostate cancer treated with docetaxel? BJU Int 2009; in press
  • 73
    Armstrong AJ, Garrett-Mayer ES, Yang YC et al. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007; 13: 6396403
  • 74
    Banu E, Banu A, Medioni J et al. Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: modelization using a standardized set of response criteria. Prostate 2007; 67: 15439